Cargando…

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis

SIMPLE SUMMARY: BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of stage III melanoma in patients with BRAF V600 mutations in clinical trials. However, little is known about how these therapies compare to each other in everyday practice. The aim of our study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Meza, Melissa M., Blokx, Willeke A. M., Bonenkamp, Johannes J., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Boers-Sonderen, Marye J., De Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen, Van Not, Olivier J., Piersma, Djura, Van Rijn, Rozemarijn S., Stevense-den Boer, Marion, Van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Van den Eertwegh, Alfonsus J. M., Suijkerbuijk, Karijn P. M., Wouters, Michel W. J. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857200/ https://www.ncbi.nlm.nih.gov/pubmed/36672358 http://dx.doi.org/10.3390/cancers15020409

Ejemplares similares

The unfavorable effects of COVID‐19 on Dutch advanced melanoma care
por: van Not, Olivier J., et al.
Publicado: (2021)

Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
por: Verver, Danielle, et al.
Publicado: (2021)

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2022)

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
por: van Not, Olivier J., et al.
Publicado: (2023)

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands
por: van Breeschoten, Jesper, et al.
Publicado: (2021)

Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study
por: van der Kooij, Monique K., et al.
Publicado: (2021)

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
por: Blankenstein, Stephanie A., et al.
Publicado: (2020)

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
por: Verheijden, Rik J, et al.
Publicado: (2020)

Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response
por: van der Kooij, Monique K., et al.
Publicado: (2020)

Real‐world outcomes of advanced melanoma patients not represented in phase III trials
por: van Zeijl, Michiel C. T., et al.
Publicado: (2020)

Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases
por: Ismail, Rawa K., et al.
Publicado: (2020)

Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
por: Biewenga, Maaike, et al.
Publicado: (2021)

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice
por: van Zeijl, Michiel C. T., et al.
Publicado: (2021)

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
por: Leeneman, Brenda, et al.
Publicado: (2020)

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
por: Schouwenburg, Maartje G., et al.
Publicado: (2019)

Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
por: Jochems, Anouk, et al.
Publicado: (2019)

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
por: Mulder, E. E. A. P., et al.
Publicado: (2021)

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
por: Franken, M.G., et al.
Publicado: (2021)

Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2009)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2008)

Targeted therapies in renal cell cancer: recent developments in imaging
por: van der Veldt, Astrid A. M., et al.
Publicado: (2010)

LBA79 Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study
por: de Joode, K., et al.
Publicado: (2020)

Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
por: Verheijden, Rik J., et al.
Publicado: (2023)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Nipple Aspirate Fluid at a Glance
por: Patuleia, Susana I. S., et al.
Publicado: (2021)

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer
por: Holleman, Marscha S., et al.
Publicado: (2022)

Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma
por: van den Brom, Rob R. H., et al.
Publicado: (2018)

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
por: de Joode, Karlijn, et al.
Publicado: (2020)

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2011)

Comparison of Different Promoter Methylation Assays in Breast Cancer
por: Suijkerbuijk, Karijn P. M., et al.
Publicado: (2010)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Low Levels of BNIP3 Promoter Hypermethylation in Invasive Breast Cancer
por: van Diest, Paul J., et al.
Publicado: (2010)

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study
por: van der Hiel, Bernies, et al.
Publicado: (2017)

Response to Imported Case of Marburg Hemorrhagic Fever, the Netherlands
por: Timen, Aura, et al.
Publicado: (2009)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node
por: van den Hout, Mari F. C. M., et al.
Publicado: (2016)

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
por: Tullemans, Bibian M. E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jpo3v72liirhae93pfo22o1n56